VHL Share Price

Open 0.14 Change Price %
High 0.14 1 Day 0.00 0.00
Low 0.14 1 Week 0.00 0.00
Close 0.14 1 Month 0.00 0.00
Volume 22950 1 Year 0.00 0.00
52 Week High 1.60
52 Week Low 1.48
VHL Important Levels
Resistance 2 0.14
Resistance 1 0.14
Pivot 0.14
Support 1 0.14
Support 2 0.14
ASX Australia Most Active Stocks
EHL 0.09 12.50%
EHL 0.09 12.50%
AGO 0.01 0.00%
AGO 0.01 0.00%
AGO 0.01 0.00%
DUE 3.02 1.00%
DUE 3.02 1.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
HHM 0.02 100.00%
SMD 0.02 100.00%
SMD 0.02 100.00%
ANO 0.03 50.00%
ANO 0.03 50.00%
ANO 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
More..
ASX Australia Top Losers Stocks
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
GDY 0.01 -50.00%
NGY 0.02 -50.00%
TRM 0.02 -33.33%
TRM 0.02 -33.33%
BYL 0.07 -30.00%
More..

Virax Holdings Ltd (ASX: VHL)

VHL Technical Analysis 5
As on 12th Dec 2014 VHL Share Price closed @ 0.14 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 0.01 & Strong Buy for SHORT-TERM with Stoploss of 0.01 we also expect STOCK to react on Following IMPORTANT LEVELS.
VHL Target for June
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
VHL Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.virax.com.au
VHL Address
VHL
Kew Junction Tower
Suite 220
Kew, VIC 3101
Australia
Phone: 61 3 9854 6230
Fax: 61 3 9853 5134
Interactive Technical Analysis Chart Virax Holdings Ltd ( VHL ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Virax Holdings Ltd
VHL Business Profile
Virax Holdings Limited, a biopharmaceutical company, discovers and develops novel immunotherapeutic products for the treatment of chronic infectious diseases and cancer in Australia. It primarily develops immunotherapeutics based on its Co-X-Gene and fowlpox virus delivery technologies. The company’s Co-X-Gene based vaccines are used for the treatment of HIV, hepatitis B virus, and prostate cancer. Its lead product includes VIR201, an HIV/AIDS immunotherapeutic product, which has completed two Phase I/IIa clinical trials. The company also develops VIR501, a therapeutic prostate cancer vaccine; and therapeutic human papilloma virus (HPV) vaccine. In addition, it licenses its technology to produce immunotherapeutic products, including TG4001, a cancer vaccine that has completed Phase IIb CIN2/3/HPV trial; and TG4010, a lung cancer vaccine, which has completed Phase IIb trial. Virax Holdings Limited is based in Kew, Australia.